Xiaoyu Zhang^1,#, RenFei Zong^1,#, Yan Sun¹, Nan Chen², Kunyao Zhu¹, Hang Tong¹, Tinghao Li¹, Junlong Zhu¹, Zijia Qin¹, Linfeng Wu¹, Aimin Wang¹, Weiyang He^1,*

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.072084 - 19 January 2026

Abstract Objective: While cisplatin-based chemotherapy is pivotal for advanced bladder cancer, acquired resistance remains a major obstacle. This study investigates key molecular drivers of this resistance and potential reversal strategies. Methods: We established GC (Gemcitabine and Cisplatin)-resistant T24-R and UC3-R cell lines from T24 and UM-UC-3 (UC3) cells. Transcriptomic and proteomic analyses identified differentially expressed molecules. Apoptosis and cell viability were assessed by flow cytometry and CCK-8 (Cell Counting Kit-8) assays, while RT-qPCR (Reverse Transcription Quantitative Polymerase Chain Reaction) and Western blot analyzed gene and protein expression. Immunofluorescence evaluated FAK (Focal Adhesion Kinase) phosphorylation, and a… More >

Sha Hu^1,2,#, Wenjing Wang^1,#, Qianfang Hu^3,#, Rujuan Zheng^1,2, Qinghe Huang^1,2, Hui Shi^1,2, Xinyuan Ding^3,*, Wenjuan Wang^1,2,*, Zengyan Zhu^1,2,*

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.068967 - 19 January 2026

Abstract Objectives: Acquired resistance to paclitaxel represents a critical barrier to the effective chemotherapy of non-small cell lung cancer (NSCLC). The present study aimed to elucidate the molecular and pharmacological mechanisms promoting paclitaxel resistance in NSCLC and to explore potential strategies for overcoming this resistance. Methods: Here, we report an integrated pharmacological and analytical approach to quantify paclitaxel disposition and overcome resistance in a A549/TAX cell model (paclitaxel-resistant A549 cells). Results: Cell counting kit-8 (CCK-8) assay, colony formation, and apoptosis assays confirmed that A549/TAX cells exhibited marked resistance to paclitaxel relative to parental A549 cells. Based on… More >

Jianfa Wu^1,2,3, Huang Chen³, Sihong Wang^1,2, Lei Peng^1,2, Xiaoying Hu^1,2, Zhou Liu^1,2,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070542 - 30 December 2025

Abstract Objectives: Ribosomal protein S6 kinase A2 (RPS6KA2) has been identified as a potential prognostic biomarker in several cancers, including breast cancer, glioblastoma, and prostate cancer. However, its functional significance in ovarian cancer is not well characterized. This study was designed to explore the therapeutic relevance of modulating RPS6KA2 in the context of ovarian cancer, particularly in relation to cisplatin resistance. Methods: The expression levels of RPS6KA2 and key regulators involved in autophagy and ferroptosis were assessed using quantitative reverse transcription-PCR, immunofluorescence staining, immunohistochemistry, and western blotting. Prognostic associations were conducted using the Kaplan-Meier Plotter database.… More >

Ranran Yang^1,2,3,#, Dan Yuan^2,#, Chaohan Liang^4,#, Siying Zhu⁴, Jie Huang², Yingqi Zhang⁴, Weiling He⁵, Qinghai Li^1,*, Hong Zhang^2,*

Oncology Research, Vol.33, No.12, pp. 3945-3971, 2025, DOI:10.32604/or.2025.064463 - 27 November 2025

Abstract Background: Colorectal cancer (CRC) is a predominant contributor to global cancer-associated mortality worldwide. Oxaliplatin (OXP), a foundational chemotherapeutic agent for CRC, often exhibits limited efficacy due to the emergence of drug resistance. Although endothelin-1 (EDN1) has been implicated in tumor drug resistance, its role in oxaliplatin resistance in CRC remains poorly defined. This work aimed to define how EDN1 contributes to oxaliplatin resistance and to explore its potential as a therapeutic target. Methods: Public genomic datasets were analyzed to confirm EDN1 upregulation in colorectal cancer (CRC) and its association with poor prognosis. EDN1 expression was… More >

Russel J. Reiter^1,*, Ramaswamy Sharma^2,*, Walter Manucha³, Walter Balduini⁴, Doris Loh⁵, Demetrios A. Spandidos⁶, Alejandro Romero⁷, Vasiliki E. Georgakopoulou⁸, Wei Zhu⁹

BIOCELL, Vol.49, No.11, pp. 2033-2067, 2025, DOI:10.32604/biocell.2025.067661 - 24 November 2025

Abstract The development of cancer cell resistance to conventional treatments continues to be a major obstacle in the successful treatment of tumors of many types. The discovery of a highly efficient direct and indirect free radical scavenger, melatonin, in the mitochondrial matrix may be a factor in determining both the occurrence of cancer cell drug insensitivity as well as radioresistance. This relates to two of the known hallmarks of cancer, i.e., exaggerated free radical generation in the mitochondria and the development of Warburg type metabolism (glycolysis). The hypothesis elaborated in this report assumes that the high… More >

Jingcheng Lyu^1,2,#, Ruiyu Yue^1,2,#, Yichen Zhu^1,2, Ye Tian^1,2,*, Xinyi Hu^1,2,*

Canadian Journal of Urology, Vol.32, No.5, pp. 411-422, 2025, DOI:10.32604/cju.2025.066758 - 30 October 2025

Abstract Objective: Urothelial carcinoma (UC) remains a prevalent malignancy with high recurrence and chemoresistance rates despite gemcitabine-cisplatin (GC) chemotherapy. The study aimed to identify clinical risk factors for chemoresistance in advanced UC patients and develop a predictive model. Method: A retrospective analysis was conducted on 375 UC patients who received postoperative GC chemotherapy between 2013 and 2024. Patients were categorized into chemotherapy-resistant (CR, n = 91) and non-chemotherapy resistant (NCR, n = 284) groups based on tumor progression. Clinical, pathological, and laboratory variables were compared using t-tests and chi-square tests. Kaplan-Meier assessed overall survival (OS), and binary More >

MOEKA NAKASHIMA, NAOKO SUGA, AKARI FUKUMOTO, SAYURI YOSHIKAWA, SATORU MATSUDA^*

Oncology Research, Vol.33, No.5, pp. 1007-1017, 2025, DOI:10.32604/or.2025.059657 - 18 April 2025

Abstract Malignant tumors are heterogeneous diseases characterized by uncontrolled cell proliferation, invasion, metastasis, and/or recurrence of their malignancies. In particular, cancer stem cells (CSCs) within these tumors might be responsible for the property of invasiveness and/or therapies-resistance. CSCs are a self-renewing, awfully tumorigenic subpopulation of cancer cells, which are notorious for strong chemoresistance and are frequently responsible the aggravated invasion, metastasis, and/or recurrence. Developing targeting therapies against CSCs, therefore, may be deliberated a more encouraging mission for the greater cancer therapy. Innovation for a more potent anti-CSC treatment has been required as soon as possible.… More > Graphic Abstract

LUIZ FERNANDO LOPES SILVA^1,#, JULIETE NATHALI SCHOLL^1,#, AUGUSTO FERREIRA WEBER¹, CAMILA KEHL DIAS¹, PAULINE RAFAELA PIZZATO², VINíCIUS PIERDONá LIMA¹, JEAN SÉVIGNY^3,4, ANA MARIA OLIVEIRA BATTASTINI¹, FABRÍCIO FIGUEIRÓ^1,2,*

Oncology Research, Vol.33, No.4, pp. 951-964, 2025, DOI:10.32604/or.2024.055508 - 19 March 2025

Abstract Objectives: Glioblastoma (GB) is a grade IV glial tumor characterized by high malignancy and dismal prognosis, primarily due to high recurrence rates and therapeutic resistance. The epidermal growth factor receptor (EGFR), a receptor tyrosine kinase (RTK), regulates signaling pathways, including cell growth, proliferation, survival, migration, and cell death. Many cancers utilize immune checkpoints (ICs) to attenuate immune responses. CD73 is an enzyme that functions as an IC by hydrolyzing AMP to adenosine, suppressing immune cells in the tumor microenvironment. However, the role of CD73 in resistance to EGFR inhibitors is poorly understood. This study aims… More >

CHUAN JIANG^1,2, CHUNLEI LIU^1,3, XI YAO^1,3, JINGYA SU^1,2, WEI LU^1,3, ZHENGBO WEI^3,*, YING XIE^1,2,*

Oncology Research, Vol.32, No.12, pp. 1935-1948, 2024, DOI:10.32604/or.2024.052244 - 13 November 2024

Abstract Background: Head and neck squamous cell carcinoma (HNSCC) is a prevalent form of cancer globally, with chemoresistance posing a major challenge in treatment outcomes. The efficacy of the commonly used chemotherapeutic agent, cisplatin, is diminished in patients with poor prognoses. Methods: Various bioinformatics databases were utilized to examine Carboxylesterase 1 (CES1) gene expression, clinicopathologic features, patient survival analysis, and gene function. An organoid model of HNSCC was established, along with the induction of drug-resistant HNSCC in the organoid model. CES1 expression was assessed using qRT-PCR and Western Blot, and differential markers were identified through transcriptome… More >

SHAN JIANG^1,2, XIUFENG LIN², YANFEI CHEN³, XINNING LI³, JIALI KANG^1,4,*

BIOCELL, Vol.48, No.8, pp. 1265-1273, 2024, DOI:10.32604/biocell.2024.051478 - 02 August 2024

Abstract Background: Despite improvements in objective response rates to cisplatin-based combination chemotherapy, the majority of advanced ovarian cancer remains suboptimal, resulting in poor survival. it has been found that non-coding RNAs (ncRNAs) not only participate in the transmission of signals between various cells but also participate in tumor immunity and anti-tumor immune responses, thereby regulating tumor occurrence and development. However, the function and detailed mechanism of ultraconserved RNA (ucRNA) in ovarian cancer chemoresistance is still unclear. Methods: Western blotting assay, Quantitative real-time PCR analysis (qPCR), and Kaplan-Meier Plotter analysis were performed to analyze the expression and prognosis… More >